Drug Profile

Recombinant anti-CD73 fully human monoclonal antibody - Shanghai Fosun Pharmaceutical

Latest Information Update: 28 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Fosun Pharmaceutical
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 May 2026 No recent reports of development identified for preclinical development in Solid-tumours in China (Parenteral, Injection)
20 Apr 2022 Preclinical trials in Solid tumours in China (Parenteral) (Shanghai Fosun Pharmaceutical pipeline, April 2022)
20 Apr 2022 The US FDA approves IND application for Recombinant anti-CD73 fully human monoclonal antibody in Solid tumours (Shanghai Fosun Pharmaceutical pipeline, April 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com